Circassia Pharmaceuticals’ (CIR) “Buy” Rating Reaffirmed at Peel Hunt

Peel Hunt reissued their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a report released on Thursday morning.

A number of other equities analysts have also recently commented on CIR. Royal Bank of Canada lowered their price target on Circassia Pharmaceuticals from GBX 86 ($1.12) to GBX 81 ($1.06) and set a sector performer rating for the company in a report on Wednesday, October 17th. Numis Securities reissued a buy rating and set a GBX 140 ($1.83) price target on shares of Circassia Pharmaceuticals in a report on Thursday, September 27th.

Shares of Circassia Pharmaceuticals stock traded up GBX 5.60 ($0.07) during trading on Thursday, reaching GBX 62.20 ($0.81). 182,089 shares of the company’s stock were exchanged.

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.

Read More: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply